Indian pharma sector was underperforming since 2015-16 and this change in trajectory could be a start to revamp its long-term outlook, in-terms of re- ...
Read more: Deep correction unlikely, allocate 5% of the portfolio to defence stocks: Geojit's Vinod Nair